Skip to main content
OpenTrials
Completed

NCT Number: NCT03348579

Hospital-acquired Pneumonia in Intensive Care Unit

hospital-acquired pneumonia are a common disease in intensive care unit. The prevention, the diagnosis and the treatment of hospital acquired pneumonia are a frequent challenge. Nevertheless it seems that there are great differences in standard of care between hospitals. The investigators hypothesized that medical education and implementation of evidence-base guidelines can reduce the duration of mechanical ventilation in patients presenting of hospital acquired pneumonia

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hospital Acquired Pneumonia Cross Infection Disease Attributes Healthcare-Associated Pneumonia Iatrogenic Disease Infections Inflammation Lung Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Ventilator-Associated Respiratory Tract Diseases Respiratory Tract Infections Sepsis Systemic Inflammatory Response Syndrome Ventilator-associated Pneumonia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de NANTES

Nantes, 44093, France

About this study

The before period (phase 1) will consist of all consecutive patients admitted to the participating ICUs before the national guidelines publication concerning healthcare associated pneumonia.

The second period (phase 2) will consist of all consecutive patients admitted to the participating ICUs after the publication of the national guidelines publication concerning healthcare associated pneumonia.

Afterward, an interphase will occur during which all physicians, residents, physiotherapists and nurses will receive a formal training for the processes and procedures related to the new guidelines published in september 2017.

In the intervention group, on top of the standard training, the centers receive an analysis of the evolution of the practices of their center and the future of their patients between phases 1 and 2, as well as these same values for the data set. The centers are then called to conduct a meeting to determine their priority improvement points based on this audit.

The third and final period (phase 3) will consist of all consecutive patients admitted to the participating ICUs after the formal training.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years ; IGS-II score > 15 ; Hospital stay >= 3 days

Exclusion criteria

  • Community-acquired pneumonia, pregnant women, refusal to participate

Treatment and study plan

Guidelines publication and application

Other

Passing recommendations on using the guidelines in the intensive care units

Targeted experience feedback

Other

Targeted experience feedback": On top of the standard training, the centers receive an analysis of the evolution of the practices of their center and the future of their patients between phases 1 and 2, as well as these same values for the data set. The centers are then called to conduct a meeting to determine their priority improvement points based on this audi

Primary outcomes

  1. Unit length of stay

    Time frame: 28 days

    Duration of ICU hospitalization Safety Issue: NA

Secondary outcomes

  1. Intensive Care Unit free-days at day 28

    Time frame: 28 days

    The number of days from day 1 to day 28 on which a patient is alive outside of intensive care unit Safety Issue

  2. Hospital-acquired pneumonia

    Time frame: 28 days

    definition based on the appearance of a new infiltrate or changes in an existing infiltrate on chest X-ray associated with any two of the following clinical signs: body temperature >38°C, leucocytosis >12,000/ml or leukopenia <4000/ml, and purulent pulmonary secretions that were associated with a positive quantitative or semi-quantitative bacteriological culture of a respiratory tract sample.

  3. Composite measure of compliance to guidelines

    Time frame: 28 days

    defined as the total number of performed eligible measures divided by the total number of measures for which each patient was eligible

  4. Empirical treatment failure

    Time frame: 28 days

    Defined as one or more pathogen involved in the pneumonia is not susceptible to the antibiotics used empirically

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Collaborators

  • Société Française d'Anesthésie et de Réanimation

Registry information

Official study title

Hospital Acquired and Ventilator Associated Pneumonia : Impact of the New French Guidelines on Patients Care and Outcomes.

Acronym: PNEUMOCARE

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Nov 21, 2017
Registry last updated
May 12, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.